Chatzis DG, Magounaki K, Pantazopoulos I, Bhaskar SMM. COVID-19 and the cardiovascular system-current knowledge and future perspectives. World J Clin Cases 2022; 10(27): 9602-9610 [PMID: 36186205 DOI: 10.12998/wjcc.v10.i27.9602]
Corresponding Author of This Article
Dimitrios G Chatzis, MD, PhD, Chief Doctor, Consultant Physician-Scientist, Lecturer, Medical School, European University Cyprus, 6 Diogenis Street, Nicosia 2404, Cyprus. dimitrioschatzis@yahoo.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 26, 2022; 10(27): 9602-9610 Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9602
COVID-19 and the cardiovascular system-current knowledge and future perspectives
Dimitrios G Chatzis, Kalliopi Magounaki, Ioannis Pantazopoulos, Sonu Menachem Maimonides Bhaskar
Dimitrios G Chatzis, Medical School, European University Cyprus, Nicosia 2404, Cyprus
Kalliopi Magounaki, Department of Internal Medicine, KAT General Hospital, Athens 14561, Greece
Ioannis Pantazopoulos, Department of Emergency Medicine, Faculty of Medicine, University of Thessaly, Larissa 41500, Greece
Sonu Menachem Maimonides Bhaskar, NSW Brain Clot Bank, NSW Health Pathology, Sydney, NSW 2170, Australia
Sonu Menachem Maimonides Bhaskar, Department of Neurology and Neurophysiology, Liverpool Hospital and South Western Sydney Local Health District, Sydney, NSW 2170, Australia
Author contributions: Chatzis DG, Magounaki K, Pantazopoulos I, and Bhaskar SMM wrote the manuscript. All authors have equally contributed in the preparation of this manuscript.
Conflict-of-interest statement: All authors report no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dimitrios G Chatzis, MD, PhD, Chief Doctor, Consultant Physician-Scientist, Lecturer, Medical School, European University Cyprus, 6 Diogenis Street, Nicosia 2404, Cyprus. dimitrioschatzis@yahoo.com
Received: May 15, 2022 Peer-review started: May 15, 2022 First decision: June 8, 2022 Revised: June 29, 2022 Accepted: August 16, 2022 Article in press: August 16, 2022 Published online: September 26, 2022
Abstract
The current coronavirus disease 2019 (COVID-19) pandemic has had devastating impact on populations around the world. The high mortality rates in patients with COVID-19 has been attributed to the influence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), its causative viral agent, on several physiological systems in human body, including the respiratory, cardiovascular, and neurological systems. There is emerging evidence on propensity of this virus to attack cardiovascular system. However, various pathophysiological mechanisms by which SARS-CoV-2 interacts with cardiovascular system and leads to high morbidity and mortality, including cardiovascular complications, are poorly understood. This mini review aims to provide an update on the current knowledge and perspectives on areas of future research.
Core Tip: It is well established that severe acute respiratory syndrome coronavirus-2 has a high propensity to attack cardiovascular system with various clinical manifestations namely myocarditis and myocardial injury, cardiac arrest, acute coronary syndromes, hypercoagulability and venous thromboembolism, as well as heart failure. Currently, there is no established, specific therapy for the treatment of coronavirus disease-induced cardiovascular involvement and there is ongoing research on this topic.
